biib

Biotech Stocks to Love: Biogen Inc (NASDAQ:BIIB), OncoGenex …

Many individual investors have opted to invest in biotech ETFs and mutual funds. The XBI and SBIO funds have performed well because they focus more on small and mid-sized biotech companies. The IBB, which has emerged as something of a proxy for the industry for many investors, is weighted much more heavily to bigger, more proven biotech companies.The volatility of […]

These are the Biggest Risk to Biotech – Stocks to Watch – Barrons.com

By Ben LevisohnIn a note this morning, BofA Merrill Lynch’s Christina Giannini and team note that the risk for big-cap biotech stocks–think Gilead Sciences (GILD) and Biogen (BIIB)–and small-cap biotech stocks–everything else–are quite different. They explain:
Associated Press

Biotech is now more passive than actively managed: Perhaps due to the difficulty picking stocks within such an idiosyncratic sector given the complicated science […]

Goldman Sachs: Hedge Biotech Stocks Now – Stocks to Watch …

By Steve SearsGoldman Sachs is telling clients to hedge the bio-technology sector in anticipation of a sharp decline. Early Monday, the bank told clients to buy SPDR S&P Biotech ETF (XBI) December $230 puts. During the pre-market, the ETF was priced at $255, and the put was at $15.50.
SSPL via Getty Images
“These puts are about 10% out-of-the-money and cost about […]

More Market Nothingness and Biotech Has Me Cautious

This maddening sideways chop continues and the best “risk on” sector, biotech, looks heavy and tired.  The leaders in this space are heavy, AMGN has a bearish head and shoulder pattern going on and CELG and BIIB just cant stop stepping on their feet. GILD acts the best of the big four biotechs.  The other biggie, REGN, continues to hang […]

A Biotech Bottom?

By Ben LevisohnIt’s been a bad, bad week for biotech stocks. The iShares Nasdaq Biotech Index ETF (IBB) had dropped 9.3% this week through Thursday’s close, while Amgen (AMGN), Biogen Idec (BIIB), and Celgene (CELG) also suffered big losses. Evercore ISI’s Mark Schoenebaum notes that the valuations of big biotech companies is trading below that of the S&P 500 for only the […]

Expert: Biogen Is Closing In On The 'Holy Grail' For Biotech Stocks …

Related BIIBBiogen Continues To Decline After Friday’s RoutDid The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?Synageva Q1 Loss Narrower-than-Expected, Pipeline in Focus – Analyst Blog(Zacks)In this week’s episode, Estimize is joined by Joe McCann, a former biotech analyst at CR Intrinsic and the CEO of Slingshot Insights.In the episode, Joe discusses Biogen Inc (NASDAQ: BIIB) new […]

Biotech Stock Roundup: Amgen Starts Earnings Season on Strong …

Earnings season in the biotech sector started on a positive note with Amgen (AMGN – Analyst Report) reporting better-than-expected first quarter 2015 results. Meanwhile, The Medicines Co. (MDCO – Analyst Report) received some good news with an FDA advisory panel backing its antiplatelet agent. However, companies like Athersys (ATHX – Snapshot Report) and Ampio suffered setbacks on the pipeline front.Recap […]

Biotech Has Found a Home

Some biotech stocks are puking all over themselves and others act like drunks walking in traffic.  The IBB has found a home at its 50 day moving average which coincides with its daily uptrend line.This is a huge spot for support and if it breaks lower it could do a quick cascade to the 100 moving average which is down […]

Stocks rally as dollar weakens; Nike tops estimates

Traders work on the floor of the New York Stock Exchange on March 20, 2015. AP Photo/Richard DrewU.S. stocks surged on Friday, lifting the Nasdaq Composite (COMP) to a 15-year high, as Wall Street embraced quarterly results from Nike (NKE) and others and the U.S. dollar softened against other global currencies.”The fact that the Nasdaq is above 5,000 from technical […]

New Biotech ETFs Highlight Evolving Growth Opportunities

The biotechnology story is one that continues to highlight evolving growth opportunities in the medical field. Whether you are a believer in the high valuations or not, these stocks have consistently posted double digit gains for more than half a decade and enthralled investors with their resiliency. That makes biotechnology companies worthy of consideration for those that are seeking high […]